Alain Claude-Marie Daugan

This inventor holds 26 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Icos Corporation, Lilly Icos LLC, Glaxosmithkline Intellectual Property Development Limited. Active years: 1997-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alain Claude-Marie Daugan. Retrieved from https://idiyas.com/inventor/alain-claude-marie-daugan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 7)

% Patents Active = 57.7

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 8)

Average Co-Inventor Count = 2.0

ph-index = 11

Forward Citations = 350(Granted Patents)

Location History:

Marly le Roi Cedex, FR (2000)
Les Ulis, FR (1997 - 2022)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

Laboratoires Glaxo S.a.

patents

6. 1 out of 2,198

Smithkline Beecham Corporation

patents

Years Active: 1997-2022

Loading Chart...

Areas of Expertise:

Heterocyclic Amides

Kinase Inhibitors

Quinolinone Derivatives

Carboline Derivatives

PDE5 Inhibitors

Cardiovascular Disorders

Erectile Dysfunction

Cyclic GMP

Phosphodiesterase Inhibitors

Isoquinoline Derivatives

Anti-Tumor Properties

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11485710 - Heterocyclic amides as kinase inhibitors (2022-11-01),

2. 10899716 - Heterocyclic amides as kinase inhibitors (2021-01-26),

3. 10590085 - Heterocyclic amides as kinase inhibitors (2020-03-17),

4. 9855260 - Quinolinone derivatives (2018-01-02),

5. 9061998 - Quinolinone derivatives (2015-06-23),

6. 7122554 - Carboline derivatives (2006-10-17),

7. 6984641 - Carboline derivatives as PDE5 inhibitors (2006-01-10),

8. 6962918 - Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction (2005-11-08),

9. 6911542 - Pyrazino[1',2′:1,6]pyrido[3,4b]indole derivatives (2005-06-28),

10. 6872721 - Derivatives of 2,3,6,7,12,12a-hexahydropyrazino-[1',2′:1,6]pyrido[3,4b]-indole-1,4-dione (2005-03-29),

11. 6858620 - Condensed pyridoindole derivatives (2005-02-22),

12. 6838456 - Condensed pyridoindole derivatives (2005-01-04),

13. 6784179 - Tetracyclic derivatives, process of preparation and use (2004-08-31),

14. 6608065 - Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction (2003-08-19),

15. 6552022 - Benzamide derivatives and their use as ApoB-100 secretion inhibitors (2003-04-22),

Title: **Alain Claude-Marie Daugan: A Trailblazer in Kinase Inhibition Innovations**

Introduction

Alain Claude-Marie Daugan, based in Les Ulis, France, is a distinguished inventor with a remarkable portfolio of 26 patents. His innovative work primarily focuses on the development of unique compounds that serve as crucial kinase inhibitors, reflecting his significant contributions to the field of medicinal chemistry.

Latest Patents

One of Alain's latest patents, titled "Heterocyclic amides as kinase inhibitors," showcases groundbreaking compounds that provide innovative solutions in the treatment of various diseases. This patent emphasizes the importance of heterocyclic amides in inhibiting kinase activity, an essential mechanism in numerous cellular processes.

Career Highlights

Daugan has had a notable career with impactful positions at prominent companies, including Icos Corporation and Lilly Icos LLC. His work in these organizations has fostered advancements in pharmaceutical research and development, significantly influencing the landscape of drug discovery.

Collaborations

Throughout his career, Alain has collaborated with esteemed colleagues, including Mark W. Orme and Jason Scott Sawyer. These partnerships have led to enhanced research outcomes and have contributed positively to innovation in their respective fields.

Conclusion

Alain Claude-Marie Daugan's extensive patent portfolio and collaborative efforts underline his pivotal role in advancing kinase inhibitors. His dedication to innovation continues to inspire others in the pharmaceutical industry, showcasing the profound impact that one inventor can have on global health advancements.

Profile summary based on public USPTO records.